INVITRO AND INVIVO ANTITUMORAL ACTIVITY OF ALKYLPHOSPHONATES

被引:15
作者
RIES, UJ
FLEER, EAM
BREISER, A
UNGER, C
STEKAR, J
FENNEBERG, K
EIBL, H
机构
[1] UNIV CLIN GOETTINGEN,DEPT INTERNAL MED,DIV HAEMATOL ONCOL,ROBERT KOCH STR 40,W-3400 GOTTINGEN,GERMANY
[2] DR KARL THOMAE GMBH,DEPT CHEM RES,W-7950 BIBERACH,GERMANY
[3] ASTA PHARMA AG,DEPT CANC RES & DEV,W-6000 FRANKFURT 1,GERMANY
[4] MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY
关键词
D O I
10.1016/0959-8049(93)90583-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hexadecylphosphocholine is a new antitumour agent with a highly selective activity in chemically induced mammary tumours. It was suggested, that hexadecylphosphocholine is a pro-drug, cleavable by phospholipases C and/or D, creating hexadecanol or hexadecylphosphate as the active principle. To test this hypothesis, the antineoplastic activity of three alkylphosphonates, cleavable either by phospholipase C or D, are compared with those of the parent compound, hexadecylphosphocholine. Cell culture experiments, in which radiolabelled alkylphosphonates were incubated with a neoplastic cell line, showed no metabolism even after 3 days of incubation. In in vivo experiments with dimethylbenzanthracene-induced rat mammary carcinomas, all three alkylphosphonates showed antineoplastic activity, although none of them reached the high activity of hexadecylphosphocholine. These results indicate that the antitumoral activity of alkylphosphocholines and alkyl lysophosphatidylcholines is due to direct toxicity and not dependent on metabolism by phospholipases C or D or related enzymes.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 19 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   A NEW, SENSITIVE DETERMINATION OF PHOSPHATE [J].
EIBL, H ;
LANDS, WEM .
ANALYTICAL BIOCHEMISTRY, 1969, 30 (01) :51-&
[3]   METABOLISM OF ETHER PHOSPHOLIPIDS AND ANALOGS IN NEOPLASTIC-CELLS [J].
FLEER, EAM ;
UNGER, C ;
KIM, DJ ;
EIBL, H .
LIPIDS, 1987, 22 (11) :856-861
[4]  
FLEER EAM, 1990, ONKOLOGIE, V13, P295
[5]   CHARACTERIZATION OF THE ANTITUMOR-ACTIVITY OF HEXADECYLPHOSPHOCHOLINE (D-18506) [J].
HILGARD, P ;
STEKAR, J ;
VOEGELI, R ;
ENGEL, J ;
SCHUMACHER, W ;
EIBL, H ;
UNGER, C ;
BERGER, MR .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (09) :1457-1461
[6]  
HILGARD P, 1989, P AM ASSOC CANC RES, V30, P2310
[7]   EFFECTS OF ANTINEOPLASTIC PHOSPHOLIPIDS ON PARAMETERS OF CELL-DIFFERENTIATION IN U937 CELLS [J].
HOCHHUTH, C ;
BERKOVIC, D ;
EIBL, H ;
UNGER, C ;
DOENECKE, D .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (05) :459-466
[8]  
HUDSON L, 1976, PRACTICAL IMMUNOLOGY, P29
[9]  
KOVATCHEV S, 1978, ENZYMES LIPID METABO, P221
[10]  
MUNDER PG, 1976, IMMUNOPATHOLOGY, V8, P411